Clinical Trial Detail
Contact
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| NCT ID | NCT01336634 |
| Title | Study of Selective BRAF Kinase Inhibitor Dabrafenib Monotherapy Twice Daily and in Combination With Dabrafenib Twice Daily and Trametinib Once Daily in Combination Therapy in Subjects With BRAF V600E Mutation Positive Metastatic (Stage IV) Non-small Cell Lung Cancer. |
| Recruitment | Completed |
| Gender | both |
| Phase | Phase II |
| Variant Requirements | Yes |
| Sponsors | GlaxoSmithKline |
| Indications | |
| Therapies | |
| Age Groups: | adult |
| Covered Countries | USA | NOR | NLD | ITA | GBR | FRA | ESP | DEU |
CKB BOOST